Vistagen Therapeutics (VTGN) Current Leases (2011 - 2026)
Vistagen Therapeutics (VTGN) posted Current Leases of $699000.0 for Q1 2026, up 13.29% sequentially from $617000.0 in Q4 2025, and up 24.6% YoY from $561000.0 in Q1 2025.
Vistagen Therapeutics (VTGN) Current Leases (2011 - 2026) Analysis & Trends
Vistagen Therapeutics has reported Current Leases for 14 years, with the latest figure at $699000.0 in Q1 2026.
- Quarterly Current Leases rose 24.6% year-over-year to $699000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $699000.0 (up 24.6% YoY) and the FY2026 annual result came in at $699000.0, up 24.6% from the prior year.
- Current Leases climbed to $699000.0 in Q1 2026 per VTGN's latest filing, from $617000.0 in the prior quarter.
- Over five years, Current Leases peaked at $699000.0 in Q1 2026 and troughed at $1500.0 in Q2 2022.
- A 5-year average of $400211.8 and a median of $525000.0 in 2024 frame the typical range for Current Leases.
- The sharpest annual moves came in 2022 and 2023: Current Leases sank 99.6% in 2022, then soared 34373.33% in 2023.
- Over 5 years, Current Leases stood at $1600.0 in 2022, then climbed by 18.75% to $1900.0 in 2023, then surged by 31636.84% to $603000.0 in 2024, then advanced by 2.32% to $617000.0 in 2025, then rose by 13.29% to $699000.0 in 2026.
- According to Business Quant data, Current Leases over the past three periods registered $699000.0, $617000.0, and $597000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 21.95 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 45.93 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Vistagen Therapeutics | 10.49 Mn | 10.49 Mn | - | 720,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 699,000.00 |
| Dec 31, 2025 | 617,000.00 |
| Sep 30, 2025 | 597,000.00 |
| Jun 30, 2025 | 640,000.00 |
| Mar 31, 2025 | 561,000.00 |
| Dec 31, 2024 | 603,000.00 |
| Sep 30, 2024 | 525,000.00 |
| Jun 30, 2024 | 567,000.00 |
| Mar 31, 2024 | 550,000.00 |
| Dec 31, 2023 | 1,900.00 |
| Sep 30, 2023 | 517,100.00 |
| Jun 30, 2023 | 1,700.00 |
| Mar 31, 2023 | 486,000.00 |
| Dec 31, 2022 | 1,600.00 |
| Sep 30, 2022 | 1,500.00 |
| Jun 30, 2022 | 1,500.00 |
| Mar 31, 2022 | 433,300.00 |
| Dec 31, 2021 | 300.00 |
| Sep 30, 2021 | 1,300.00 |
| Jun 30, 2021 | 378,400.00 |